Table 1

Patient characteristics

Placebo (n = 57)Pemafibrate 0.2 mg/day (n = 54)Pemafibrate 0.4 mg/day (n = 55)
Age (years)61.2 ± 10.059.8 ± 11.660.6 ± 10.1
Age ≥65 years35.1 (20)35.2 (19)34.5 (19)
Men66.7 (38)79.6 (43)72.7 (40)
BMI (kg/m2)26.0 ± 3.326.5 ± 3.825.3 ± 3.4
BMI ≥25 kg/m257.9 (33)63.0 (34)45.5 (25)
Drinking habit57.9 (33)66.7 (36)58.2 (32)
Hypertension64.9 (37)59.3 (32)60.0 (33)
Fatty liver56.1 (32)59.3 (32)47.3 (26)
Duration of diabetes (years)5.5 ± 4.54.9 ± 3.76.8 ± 5.9
No antidiabetic drug54.4 (31)55.6 (30)56.4 (31)
One antidiabetic drug22.8 (13)25.9 (14)23.6 (13)
 Sulfonylurea3.7 (2)
 DPP-4 inhibitor19.3 (11)18.5 (10)14.5 (8)
 α-Glucosidase inhibitor5.5 (3)
 Glinide3.5 (2)1.9 (1)1.8 (1)
 GLP-1 receptor agonist1.9 (1)1.8 (1)
Two antidiabetic drugs22.8 (13)18.5 (10)20.0 (11)
 Sulfonylurea/DPP-4 inhibitor19.3 (11)11.1 (6)5.5 (3)
 Sulfonylurea/α-glucosidase inhibitor3.6 (2)
 Sulfonylurea/GLP-1 receptor agonist3.6 (2)
 DPP-4 inhibitor/α-glucosidase inhibitor1.8 (1)3.7 (2)5.5 (3)
 DPP-4 inhibitor/glinide1.8 (1)1.8 (1)
 α-Glucosidase inhibitor/glinide3.7 (2)
Statin40.4 (23)33.3 (18)43.6 (24)
TG (mmol/L)3.2 ± 1.32.7 ± 1.12.9 ± 1.1
HDL-C (mmol/L)1.2 ± 0.31.2 ± 0.31.3 ± 0.7
HDL-C category <1.0 (mmol/L)28.1 (16)25.9 (14)20.0 (11)
FPG (mmol/L)7.7 ± 1.17.7 ± 1.17.4 ± 1.1
Fasting insulin (pmol/L)92.7 ± 56.683.7 ± 49.281.1 ± 40.5
HOMA-IR4.6 ± 3.04.2 ± 2.53.8 ± 1.8
HbA1c (%)7.0 ± 0.56.9 ± 0.47.0 ± 0.4
HbA1c (mmol/mol)52.9 ± 5.052.4 ± 4.752.6 ± 4.7
Glycoalbumin (%)16.9 ± 2.517.1 ± 2.017.1 ± 2.2
eGFR (mL/min/1.73 m2)73.6 ± 19.275.7 ± 14.773.3 ± 14.4
  • Data are presented as the mean ± SD for continuous parameters and % (n) for categorical parameters. DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide 1.